| Product name: |
Bcr (phospho Tyr360) rabbit pAb |
| Reactivity: |
Human;Mouse;Monkey |
| Alternative Names: |
BCR; BCR1; D22S11; Breakpoint cluster region protein; Renal carcinoma antigen NY-REN-26 |
| Source: |
Rabbit |
| Dilutions: |
Western Blot: 1/500 – 1/2000. Immunohistochemistry: 1/100 – 1/300. Immunofluorescence: 1/200 – 1/1000. ELISA: 1/40000. Not yet tested in other applications. |
| Immunogen: |
The antiserum was produced against synthesized peptide derived from human Bcr around the phosphorylation site of Tyr360. AA range:331-380 |
| Storage: |
-20C/1 year |
| Clonality: |
Polyclonal |
| Isotype: |
IgG |
| Concentration: |
1 mg/ml |
| Observed Band: |
142kD |
| GeneID: |
613 |
| Human Swiss-Prot No: |
P11274 |
| Cellular localization: |
Cell junction, synapse, postsynaptic density . Cell projection, dendritic spine . Cell projection, axon . Cell junction, synapse . |
| Background: |
A reciprocal translocation between chromosomes 22 and 9 produces the Philadelphia chromosome, which is often found in patients with chronic myelogenous leukemia. The chromosome 22 breakpoint for this translocation is located within the BCR gene. The translocation produces a fusion protein which is encoded by sequence from both BCR and ABL, the gene at the chromosome 9 breakpoint. Although the BCR-ABL fusion protein has been extensively studied, the function of the normal BCR gene product is not clear. The protein has serine/threonine kinase activity and is a GTPase-activating protein for p21rac. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008], |
